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BACKGROUND: MicroRNAs are small non-coding RNA molecules, which regulate central mechanisms of tumorigenesis. In colorectal
tumours, the combination of gain of 8q and 13q is one of the major factors associated with colorectal adenoma to adenocarcinoma
progression. Functional studies on the miR-17-92 cluster localised on 13q31 have shown that its transcription is activated by c-myc,
located on 8q, and that it has oncogenic activities. We investigated the contribution of the miR-17-92 cluster during colorectal
adenoma to adenocarcinoma progression.
METHODS: Expression levels of the miR-17-92 cluster were determined in 55 colorectal tumours and in 10 controls by real-time
RT–PCR. Messenger RNA c-myc expression was also determined by real-time RT–PCR in 48 tumours with array comparative
genomic hybridisation (aCGH) data available.
RESULTS: From the six members of the miR-17-92 cluster, all except miR-18a, showed significant increased expression in colorectal
tumours with miR-17-92 locus gain compared with tumours without miR-17-92 locus gain. Unsupervised cluster analysis clustered
the tumours based on the presence of miR-17-92 locus gain. Significant correlation between the expression of c-myc and the six
miRNAs was also found.
CONCLUSION: Increased expression of miR-17-92 cluster during colorectal adenoma to adenocarcinoma progression is associated to
DNA copy number gain of miR17-92 locus on 13q31 and c-myc expression.
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MicroRNAs (miRNAs), which are small non-coding RNA mole-
cules of 18–25 nucleotides long, have been shown to have an
important role in cancer. They function by downregulating the
expression of multiple target genes by degrading the mRNA or
blocking their translation into proteins (Bartel, 2004; Esquela-
Kerscher and Slack, 2006). These molecules regulate genes
involved in central pathways to cellular homoestasis, development
and tumorigenesis, including proliferation, apoptosis, differentia-
tion, maintenance of stem cell potency and angiogenesis (Lee et al,
1993; Wightman et al, 1993; Reinhart et al, 2000; Brennecke
et al, 2003; Chen et al, 2004; Zhao et al, 2007). Specific miRNA
expression signatures have been described in different cancer
(sub)types, and within these cancer types, different miRNA
expression signatures predict clinical outcome (Calin and Croce,
2006). In several instances, expression of miRNAs was shown to
have a function in tumour biology. One of the first studies
published described the tumour suppressor activity of let-7 in lung
cancers by downregulating the Ras oncogene (Johnson et al, 2005).
Yet, the cause of disturbed miRNA expression in cancer has only
partially been elucidated. MiRNAs appear to be frequently located
on regions of genomic instability (Calin et al, 2004) and miRNA
expression changes have been found to be associated with
chromosomal rearrangements in ovarian cancer, breast cancer,
lung cancer, melanomas and hematopoietic malignancies (Calin
et al, 2002; Hayashita et al, 2005; Lu et al, 2005; Zhang et al,
2006; Tagawa et al, 2007). Alternatively, epigenetic regulation of
miRNA expression has been described in colorectal, breast, lung
cancers and different cancer cell lines (Saito et al, 2006; Lujambio
et al, 2007).
The miR-17-92 cluster (oncomir-1), located within the third
intron of the open reading frame 13 (C13orf25), encompasses six
miRNAs (miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1 and
miR-92a-1) over B800 nucleotides on 13q31.3. Amplification of
this locus and overexpression of the miR-17-92 cluster have been
documented in B-cell lymphomas and lung cancer (Hayashita et al,
2005; Rinaldi et al, 2007). The transcription factors c-myc (8q24)
and E2F3 induce the expression of the miR-17-92 cluster. These
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sobservations are consistent with a complex regulatory network
where apoptotic and proliferative signals of c-myc and E2F1 are
tightly balanced by the expression of the miR-17-92 cluster
(O’Donnell et al, 2005; Sylvestre et al, 2007; Woods et al, 2007).
Colorectal cancer (CRC) is a heterogeneous disease, which
develops through the accumulation of multiple (epi)genetic
alterations. Accepted models of CRC progression describe muta-
tions in the Wnt pathway as an initiation event that leads to
adenoma formation (Fearon and Vogelstein, 1990). A key step in
subsequent progression to cancer is genomic instability, that
occurs in about 5% of adenomas, either through failing DNA
mismatch repair (ca. 0.5%, corresponding to 15% of all sporadic
CRCs) giving rise to the mutator phenotype marked by micro-
satellite instability (MSI), or (ca. 4.5%, corresponding to 85% of all
sporadic CRCs) (increased levels of) chromosomal instability
(CIN). The latter gives rise to aneuploid tumours showing a non-
random pattern of chromosomal alterations frequently, including
8q, 13q and 20q gains and 8p, 15q, 17p and 18q losses (Hermsen
et al, 2002). Several studies have shown gene dosage effects on
mRNA expression of genes in these gained or lost chromosomal
areas (Platzer et al, 2002). Given the gains of 13q, which includes
the miR-17-92 cluster, and gain of 8q, including frequent c-myc
amplification, led us to test the hypothesis that gene dosage effects
of the miR-17-92 cluster are associated with colorectal adenoma to
adenocarcinoma progression. Our results indicated that miR-17-92
increased expression during colorectal adenoma to adenocarcino-
ma progression is associated to miR-17-92 locus gain and
c-myc transcriptional activity.
MATERIALS AND METHODS
Patients and tumour tissues
Fresh tissue samples from 55 patients with colorectal tumours
(30 adenomas and 25 adenocarcinomas) were collected prospec-
tively at the department of pathology of the VU – University
medical center Amsterdam (VUmc) – Amsterdam, the Netherlands.
In addition, normal colorectal epithelium was obtained by
brushing the normal mucosa of colon resection margins of 10
individuals (mean age 68 years) who underwent a colon resection.
All 10 colon resection margins were located at least 10cm from the
tumour and histologically classified as cancer-free. Clinicopatho-
logical characteristics are listed in Table 1. Array comparative
genomic hybridisation (aCGH) data collected using BAC arrays
printed in house, containing B5000 DNA clones with an average
resolution along the whole genome of 1.0Mb, including contig
coverage of 13q, (http://www.vumc.nl/microarrays/index.html)
were available from the same sample of 48 patients with colorectal
tumours (GEO accession number GSE8067). Of these same
samples, total RNA was isolated using TRIzol (Invitrogen,
Carlsbad, CA, USA) following the manufacturer’s guidelines with
some modifications (http://www.vumc.nl/microarrays/index.html).
Total RNA quantity was determined with a Nanodrop ND-1000
spectrophotometer (Isogen, Hackensack, NJ, USA) and quality was
assessed in a 1% agarose gel, stained with ethidium bromide. The
study was carried out in accordance with the ethical guidelines of
the VU Medical Center of Amsterdam, concerning the use of
leftover patient material.
Quantitative RT–PCR and real-time TaqMan PCR
Quantification of c-myc mRNA expression levels was carried out
by real-time RT–PCR using SYBR Green (Applied Biosystems,
Foster City, CA, USA). First, 2mg of total RNA were incubated at
371C with 2ml of DNase I (1000U) (Invitrogen), 1mlo f1 0 buffer
and 0.5ml of Rnasin (2.500U; Promega, Madison, WI, USA) in a
final volume of 10ml. After 300, the reaction was stopped by adding
1ml of DNAse stop solution and incubating at 651C for 100. Second,
RT reactions were conducted using 1mg of DNAse-treated total
RNA as starting material, which was incubated for 100 at 701C with
1ml of oligo(dT)20 Primer (Invitrogen) in a final volume of 6ml.
Next, cDNA synthesis was completed by adding 0.25mlo f
Superscript II reverse transcriptase (300U; Invitrogen), 2mlo f
10 RT-buffer, 10ml of dNTPs (2mM), 2ml DTT (10mM) and
0.25ml of RNasin (2500U) in a final volume of 21ml, during 600 at
421C and at 951C for 50. Complementary DNA was diluted with
DEPC-treated water in a final volume of 100ml and stored at  201C
until used. Last, RT–PCR was carried out using primers directed
to c-myc (Fwd: 50 CAG CTG CTT AGA CGC TGG ATT 30, Rev:
50 GTA GAA ATA CGG CTG CAC CGA 30 with an annealing
temperature (Ta) of 601C) and the housekeeping gene b2M (Fwd:
50 TGA CTT TGT CAC AGC CCA AGA TA 30 and Rev: 50 AAT GCG
GCA TCT TCA AAC CT 30 with a Ta of 571C). For each reaction,
25ng of cDNA was used as starting material and a master mix
containing 12.5ml of SYBR Green PCR master mix (Applied
Biosystems) and 1.25ml of each of the primers sets until a final
volume of 25ml. Reactions were conducted in duplo in a 7300
Real-time PCR System (Applied Biosystems). Amplification condi-
tions comprised a denaturation step 100 at 951C and 50 cycles at
951C for 15@ and gene-specific annealing temperature for 10.
To determine the expression levels of the MiR-17-92 cluster
genes, six Taqman microRNA assays (Applied Biosystems) directed
to hsa-miR-17 (ABI 4373119), hsa-miR-18a (ABI 4373118), hsa-miR-
19a (ABI 4373099), hsa-miR-20a (ABI 4373286), hsa-miR-19b-1
(ABI 4373098), hsa-miR-92a-1 (ABI 4373013) and an endogenous
reference, the RNU48 gene (ABI 4373383), were used following the
manufacture’s protocol using 10ng of total RNA as input material. All
reactions were carried out in duplo in a 7300 Real-time PCR System
(Applied Biosystems).
Statistical analysis
The expression levels of c-myc and the miR-17-92 cluster were
calculated from the obtained Ct values using the D Ct method as
described previously (Livak and Schmittgen, 2001). Box and
scatter plots were used to appreciate the descriptive statistics of the
data. Correlation coefficients between the expression levels of the
miR-17-92 cluster genes were obtained by Spearman correlation
(SPSS 14.0 for Windows, SPSS Inc., Chicago, IL, USA). Significance
of differences in expression levels between tumours with and
without miR-17-92 locus gain was computed by the Mann–
Whitney U non-parametric test for independent samples (SPSS
14.0 for Windows). A multivariate analysis of the association of the
expression of the miR-17-92 cluster with miR-17-92 locus gain,
accounting for correlation between the six miRs in the cluster, was
carried out using a linear mixed effect model in combination
with an ANOVA F-test (‘nlme’ library R, http://cran.r-project.
org/). Unsupervised cluster analysis was carried out using the
parameters complete linkage and Euclidean distance (R software
version 2.6.1). The Pearson w
2-test was used for analysing
associations between cluster membership and presence or
absences of miR-17-92 locus DNA copy number aberrations (SPSS
14.0 for Windows).
RESULTS
The MiR-17-92 cluster is overexpressed during colorectal
adenoma to adenocarcinoma progression
To reveal the role of the miR-17-92 cluster in CRC pathogenesis,
the expression levels of the six members of this cluster (miR-17,
miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92a-1) were
determined by real-time RT–PCR in 55 colorectal tumours (30
adenomas and 25 adenocarcinomas) and 10 controls (normal
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scolorectal epithelium). The expression levels of miR-17 showed
2.6-fold increase in CRC tumours compared with controls
(P¼0.001), as well as for miR-18a, which displayed 2.4-fold
increase (P¼0.04), miR-19a with 3.4-fold increase (Po0.001),
miR-20a with 2.6 elevated expression (P¼0.001), miR-19b-1 with
1.6-fold changes (P¼0.021) and miR-92a-1 with 4.5 increased
expression (Po0.001; Figure 1A).
Next, to study whether these miRNAs play a role during
colorectal adenoma to adenocarcinoma progression, we also
analysed differences in expression between adenomas and
adenocarcinomas. Indeed, all six miRNAs showed higher expres-
sion in adenocarcinomas than in adenomas, with miR-17
expression being 1.9-fold (Po0.001) increased, miR-18a 3.4-fold
(Po0.001), miR-19a, 2.3-fold (Po0.001), miR-20a, 2.0-fold
Table 1 Clinical and histopathological features of 55 patients and their respective tumours
Tumour
ID Age Gender Tumour type Histology
Degree
dysplasia
Degree
differentiation
Presence
17–92 locus
gain
MSI
status
F19C 85 M Adenocarcinoma ND NA Moderate No MSI
F15C 65 F Adenocarcinoma ND NA Moderate No MSI
F33C 83 M Adenocarcinoma ND NA Moderate No MSI
F35C 77 M Adenocarcinoma Mucinous NA Moderate No MSI
F57C 58 F Adenocarcinoma ND NA Moderate No MSI
F39C 88 F Adenocarcinoma Mucinous NA Moderate No MSS
F27C 65 F Adenocarcinoma ND NA Moderate No MSS
F32C 65 F Adenocarcinoma ND NA Moderate No MSS
F8C 80 F Adenocarcinoma ND NA Poorly No MSS
F3C 72 F Adenocarcinoma ND NA Moderate No Unknown
F53C 63 M Adenocarcinoma Mucinous NA Moderate Unknown MSS
F36C 82 M Adenocarcinoma ND NA Well Unknown MSS
F54C 60 F Adenocarcinoma ND NA Well Yes MSS
F11C 66 M Adenocarcinoma ND NA Moderate Yes MSS
F12C 65 M Adenocarcinoma ND NA Moderate Yes MSS
F14C 71 F Adenocarcinoma ND NA Well Yes MSS
F46C 53 M Adenocarcinoma mucinous NA Moderate Yes MSS
F28C 71 F Adenocarcinoma ND NA Well Yes MSS
F30C 74 F Adenocarcinoma ND NA Poorly Yes MSS
F34C 57 F Adenocarcinoma ND NA Moderate Yes MSS
F58C 59 M Adenocarcinoma ND NA Moderate Yes MSS
F51C 47 M Adenocarcinoma ND NA Well Yes MSS
F10C 57 F Adenocarcinoma ND NA Well Yes MSS
F6C 84 F Adenocarcinoma ND NA Moderate Yes MSS
F1C 62 M Adenocarcinoma ND NA Moderate Yes MSS
F7A 70 M Adenoma Tubulovillous Severe NA No MSS
F56A 48 M Adenoma Tubular Moderate NA No MSS
F62A 80 M Adenoma Tubular Moderate NA No MSS
F50A 75 F Adenoma Tubulovillous Moderate NA No MSS
F40A 54 M Adenoma Tubular Moderate NA No MSS
F44A 75 F Adenoma Villous Moderate NA No MSS
F22A 71 F Adenoma Tubulovillous Severe NA No MSS
F23A1 77 M Adenoma Tubulovillous Moderate NA No MSS
F26A 60 M Adenoma Tubulovillous Moderate NA No MSS
F37A 58 M Adenoma Tubulovillous Severe NA No MSS
F38A1 75 M Adenoma Tubulovillous Moderate NA No MSS
F68A 52 M Adenoma Tubulovillous Moderate NA No MSS
F55A 79 F Adenoma Tubulovillous
(mucinous)
Severe NA No MSS
F58A1 59 M Adenoma Tubular Moderate NA No MSS
F59A 65 F Adenoma ND ND NA No MSS
F61A 70 M Adenoma Tubulovillous
(serrated)
Severe NA No MSS
F21A 71 F Adenoma Tubulovillous Severe NA No Unknown
F66A 75 M Adenoma Tubular Severe NA No Unknown
F20A 80 M Adenoma Tubulovillous Severe NA No MSS
F47A 62 M Adenoma Tubulovillous Moderate NA No MSS
F38A2 75 M Adenoma Tubulovillous Moderate NA No MSS
F52A 74 F Adenoma Tubular Moderate NA Unknown MSS
F58A2 59 M Adenoma Tubular Moderate NA Unknown MSS
F42A 82 M Adenoma Tubular Moderate NA Unknown MSS
F43A 79 F Adenoma Villous Moderate NA Unknown MSS
F45A 79 F Adenoma Villous Moderate NA Unknown MSS
F48A 72 M Adenoma Tubular Moderate NA Yes MSS
F23A2 77 M Adenoma Tubulovillous Severe NA Yes MSS
F60A 61 M Adenoma Tubular Moderate NA Yes MSS
F64A 55 M Adenoma Tubular Moderate NA Yes MSS
F¼female; M¼male; MSI¼microsatellite instable; MSS¼microsatellite stable; NA¼not applicable; ND¼no data.
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s(Po0.001), miR-19b-1, 2.0-fold (Po0.001) and miR-92a-1,
2.4-fold increased (Po0.001) (Figure 1B). These observations
indicate a role of miRNAs during colorectal adenoma to adeno-
carcinoma progression.
Overexpression of MiRNA cluster 17-92 members is
significantly associated with DNA copy number gain of the
miR-17-92 locus on 13q31
To study whether DNA copy number gain of miR-17-92 locus in
colorectal tumours influences the expression of the miR-17-92
cluster, 48 of the set of 55 colorectal tumours, with aCGH data
available were selected. Seventeen tumours (4 adenomas and
13 adenocarcinomas) showed 13q DNA copy number gain and
31 tumours (21 adenomas and 10 adenocarcinomas) did not show
gain of the miR-17-92 locus. Comparison of the expression levels
of each of the miR-17-92 cluster miRNAs between these two
groups showed that expression of miR-17 was increased 1.6-fold
(P¼0.05) in tumours with miR17-92 locus gain compared with
tumours with no miR-17-92 locus gain. In addition, miR-19a
showed 1.8 times elevated expression (Po0.01), miR-20a 1.7-fold
(Po0.01), miR-19b-1 1.8-fold (Po0.003) and miR-92a-1 2.0 times
increased expression (Po0.003). MiR-18a showed a 2.0-fold over
expression that did not reach statistical significance (P¼0.29)
(Figure 2). The multivariate analysis for associating expression
values of the entire miR cluster with miR17-92 locus gain revealed
a highly significant association (Po0.001).
Unsupervised hierarchical cluster analysis of the 48 tumours
with aCGH data available, revealed three clusters on the basis of
the expression levels of these six miRNAs (Figure 3). Significant
association between cluster membership and DNA copy number
status of the six miRNAs was found (P¼0.001). Cluster 1 grouped
three of samples with gain of miR17-92 locus. Cluster 2 comprised
only four of the samples with gain of miR17-92 locus and 24 of the
samples with no miR17-92 locus gain, whereas cluster 3 contained
10 of the samples with miR17-92 locus gain and seven of the
tumours with no miR17-92 locus gain (Table 2).
In conclusion, these data indicate a gene dosage effect of miR17-
92 locus amplification on expression levels of miRNA at this locus
during colorectal adenoma to adenocarcinoma progression.
Expression of the miR-17-92 cluster correlates with c-myc
expression in colorectal tumours
MiR-17-92 expression has also been shown to be regulated by the
transcription factor c-myc, located on 8q24. Consequently, to fully
investigate the mechanisms of regulation of the expression of the
miR-17-92 cluster during colorectal adenoma to adenocarcinoma
progression, we determined the correlation between the c-myc
mRNA expression on 48 tumours with miR-17-92 expression data
available. c-myc expression levels were significantly correlated to
the expression of miR17-5p (r¼0.6, Po0.001), miR-18a (r¼0.6,
Po0.001), miR-20a (r¼0.5, Po0.001), miR-19a (r¼0.5, P¼0.002),
miR-19b-1 (r¼0.4, P¼0.004) and miR-92a-1 (r¼0.4, Po0.005) as
shown in Figure 4.
The correlation between c-myc and miR-17-92 expression
illustrates the transcriptional regulation of c-myc on the miR-17-
92 cluster in CRC tumours.
DISCUSSION
Onset or substantial increase in level of CIN, depending on the
definition, is a major pathogenetic mechanism in colorectal
adenoma to adenocarcinoma progression. Presence of 13q gain
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Figure 1 Expression levels of miR-17-92 cluster in 55 colorectal tumours (30 colorectal adenomas and 25 adenocarcinomas) and 10 controls. (A) Box
plots with median, 25th and 75th percentiles and range of expression levels of each of the six components of the miR-17-92 cluster in 10 normal colon
epithelium samples and 55 colorectal tumours showed significantly increased expression in colorectal tumours compared with the controls. (B) Box plots
with median, 25th and 75th percentiles and range of expression levels of each of the six components of the miR-17-92 cluster in 30 colorectal adenomas
and 25 adenocarcinomas showed significantly increased expression in colorectal adenocarcinomas compared with the adenomas.
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sis one of the major factors associated with colorectal adenoma to
adenocarcinoma progression in CIN tumours (Hermsen et al,
2002). MicroRNAs contribute to tumorigenesis as tumour
suppressor genes or oncogenes due to their altered expression.
An effect of DNA copy number variations implicated in human
cancers on miRNAs expression has been documented previously
(Calin and Croce, 2006). The region of chromosomal gain on 13q
harbours the miR-17-92 cluster at locus 13q31.3. The six
components of this cluster are located in the third intron of the
C13orf25 gene and span nearly 800 bases. The C13orf25 gene
encodes for a protein of 70 amino acids with no putative domains
and unknown function, and is mainly considered to be a carrier of
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Figure 2 Expression levels of the six miRNA-17-92 cluster members by DNA copy number status of the miR-17-92 locus in 48 colorectal tumours. Box
plots with median, 25th and 75th percentiles and range of expression levels of each of the six miRNAs of the miR-17-92 cluster in 48 colorectal tumours
showed significantly increased expression in colorectal tumours with miR-17-92 locus gain compared with colorectal tumours without gain of the miR-17-92
locus except miR-18a.
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Figure 3 Hierarchical cluster analysis of 48 colorectal tumours based on miR-17-92 cluster expression levels. Unsupervised cluster analysis of the
expression levels of the six members of the miR-17-92 cluster across the 48 colorectal tumour groups separate the colorectal tumours with gain of the miR-
17-92 locus (clusters 1 and 3) from the tumours with no gain at this locus (cluster 2). Each column represents a colorectal tumour and each row represents
the expression of each of the components of the miR-17-92 cluster. Zero (0) represent colorectal tumours with no miR-17-92 locus gain and 1 represent
colorectal tumours with miR-17-92 locus gain.
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shown that its transcripts are mainly localised in the nucleus,
suggesting that translation of the mRNA into protein is limited.
Functional experiments have shown that whereas transfection of
the miRNAs of the miR-17-92 cluster into lung cells lead to
increased proliferation, transfection of expression constructs
containing C13orf25 cDNA did not lead to any phenotypic change
in the same cells (Hayashita et al, 2005). Interestingly, the
conservation of the exons of the C13orf25 among species is low,
compared with the miR-17-92 cluster, which is conserved in all
vertebrates (Mendell, 2008).
In this study, we described that DNA copy number gain of the
miR-17-92 locus was associated with increased expression of all
components of the miR-17-92 cluster except miR-18a. Lack of
correlation in increased expression between miR-18a and the other
members of the miR-17-92 cluster has been found when K562
leukaemia cells were transfected with a miR-17-19b construct
(Venturini et al, 2007). In this study, the influence of DNA copy
number gain of the miR-17-92 locus during CRC progression was
further supported by an unsupervised cluster analysis. This
analysis showed that the expression levels of the six miRNAs
segregated with miR-17-92 locus gain in the colorectal tumours
studied. Furthermore, the miR-17-92 cluster, located on 13q31, has
previously been described as being regulated by the transcription
factor c-myc, located on 8q24 (Chang et al, 2008). Indeed, a
positive correlation was found between c-myc expression and
expression of each of the members of the miRNA cluster in this
Table 2 Cluster membership of 48 colorectal tumours based on
expression data of the six miRNAs members of the miR-17-92 cluster
Tumours with miR17-
92 locus gain
Tumours with no
miR17-92 locus gain
Cluster 1 3 0
Cluster 2 4 24
Cluster 3 10 7
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Figure 4 Correlation between the expression of the c-myc gene and each of the miRNAs of the miR-17-92 cluster. The scatter plots of c-myc mRNA
expression (x axis) and expression of each of the miR-17-92 cluster miRNAs (y axis) show positive correlations.
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the miR-17-92 during CRC progression.
Expression profiling studies comparing controls with colorectal
adenocarcinomas had already shown increased expression of some
members of this cluster (Bandres et al, 2006; Cummins et al, 2006;
Volinia et al, 2006). However, these studies used whole normal
mucosa biopsies as source of RNA, including the mixture of non-
epithelial cells that populate the lamina propria. In this study, we
have isolated samples containing as pure a population of normal
epithelial cells as possible by brushing the surface epithelium of
the colorectal mucosa in resection specimens. This approach has
previously been validated by making cytological specimens of
these samples, and showed a high concentration of epithelial cells
(Meijer et al, 1998). Therefore, our results indicate more accurately
that differences in expression of the miRNA miR-17-92 cluster
observed between controls and colorectal carcinomas actually
reflect differences in the biology of normal and neoplastic
epithelial cells. Yet, the cause of this altered expression had not
been studied, nor was their role in colorectal adenoma to
adenocarcinoma progression. Functional studies on B-cell lym-
phomas and mouse colonocytes have shown that overexpression of
miR-17-92 on an elevated c-myc background, promotes tumour
growth by targeting E2F1 and increased angiogenesis by targeting
thrombospondin-1 (TSP1) and connective tissue growth factor
(CTGF;H eet al, 2005; O’Donnell et al, 2005; Dews et al, 2006).
Other experimentally validated target genes of some of the
components of the miR-17-92 cluster include the cyclin-depen-
dednt kinase inhibitor (CDKN1A) and the BCL2-like 11 gene
(BCL2L11) (Ivanovska et al, 2008; Koralov et al, 2008; Petrocca
et al, 2008; Ventura et al, 2008; Xiao et al, 2008). These genes
control cell cycle progression and cell death, respectively; however
their participation in CRC tumorigenesis as targets of the miR-17-
92 has not been studied. Although the exact mechanisms, that is,
the down stream targets, through which the miR-17-92 miRNAs
contribute to colorectal adenoma progression have not been
identified yet, it is tempting to speculate on the possibility of using
antagomiRs to interfere with colorectal adenoma to carcinoma
progression (Krutzfeldt et al, 2005).
The present data strongly suggest that the increase in CIN that
makes colorectal adenomas progress to adenocarcinomas not
only leads to upregulation of oncogenes but also causes the
overexpresssion of critical miRNAs.
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